BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37054526)

  • 21. Vitamin D sensitizes breast cancer cells to the action of H2O2: mitochondria as a convergence point in the death pathway.
    Weitsman GE; Koren R; Zuck E; Rotem C; Liberman UA; Ravid A
    Free Radic Biol Med; 2005 Jul; 39(2):266-78. PubMed ID: 15964518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer.
    Anbuselvam M; Easwaran M; Meyyazhagan A; Anbuselvam J; Bhotla HK; Sivasubramanian M; Annadurai Y; Kaul T; Pappusamy M; Balasubramanian B
    J Biomol Struct Dyn; 2021 Aug; 39(12):4462-4471. PubMed ID: 32567493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation.
    Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106132. PubMed ID: 35659529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of calcitriol on prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cell lines.
    Thill M; Cordes T; Hoellen F; Becker S; Dittmer C; Kümmel S; Salehin D; Friedrich M; Diedrich K; Köster F
    Anticancer Res; 2012 Jan; 32(1):359-65. PubMed ID: 22213327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
    So JY; Wahler JE; Yoon T; Smolarek AK; Lin Y; Shih WJ; Maehr H; Uskokovic M; Liby KT; Sporn MB; Suh N
    Cancer Prev Res (Phila); 2013 Sep; 6(9):959-70. PubMed ID: 23856074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells.
    Lim ST; Jeon YW; Gwak H; Kim SY; Suh YJ
    Mol Med Rep; 2018 Apr; 17(4):5581-5588. PubMed ID: 29436642
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Muthiah I; Rajendran K; Dhanaraj P; Vallinayagam S
    J Biomol Struct Dyn; 2021 Aug; 39(13):4807-4815. PubMed ID: 32580684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
    Thill M; Terjung A; Friedrich M
    Eur J Gynaecol Oncol; 2014; 35(4):341-58. PubMed ID: 25118473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer.
    So JY; Smolarek AK; Salerno DM; Maehr H; Uskokovic M; Liu F; Suh N
    PLoS One; 2013; 8(1):e54020. PubMed ID: 23326564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of vitamin D on MCF-7 breast cancer cell metabolism.
    Saracligil B; Ozturk B; Unlu A; Abusoglu S; Tekin G
    Bratisl Lek Listy; 2017; 118(2):101-106. PubMed ID: 28814091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.
    Lundqvist J; Hansen SK; Lykkesfeldt AE
    Biochim Biophys Acta; 2013 Jan; 1833(1):40-7. PubMed ID: 23085504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.
    García-Quiroz J; García-Becerra R; Barrera D; Santos N; Avila E; Ordaz-Rosado D; Rivas-Suárez M; Halhali A; Rodríguez P; Gamboa-Domínguez A; Medina-Franco H; Camacho J; Larrea F; Díaz L
    PLoS One; 2012; 7(9):e45063. PubMed ID: 22984610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
    García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
    Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
    J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ferrotoxicity and Its Amelioration by Calcitriol in Cultured Renal Cells.
    Annamalai C; Seth R; Viswanathan P
    Anal Cell Pathol (Amst); 2021; 2021():6634429. PubMed ID: 33680716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
    Krishnan AV; Swami S; Peng L; Wang J; Moreno J; Feldman D
    Endocrinology; 2010 Jan; 151(1):32-42. PubMed ID: 19906814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism.
    Sharma V; Fretwell D; Crees Z; Kerege A; Klopper JP
    Thyroid; 2010 Oct; 20(10):1103-11. PubMed ID: 20860424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer.
    Swami S; Krishnan AV; Wang JY; Jensen K; Horst R; Albertelli MA; Feldman D
    Endocrinology; 2012 Jun; 153(6):2576-87. PubMed ID: 22454149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
    Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
    Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists.
    Morshed AKMH; Al Azad S; Mia MAR; Uddin MF; Ema TI; Yeasin RB; Srishti SA; Sarker P; Aurthi RY; Jamil F; Samia NSN; Biswas P; Sharmeen IA; Ahmed R; Siddiquy M; Nurunnahar
    Mol Divers; 2023 Dec; 27(6):2651-2672. PubMed ID: 36445532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.